Of the major cancers, pancreatic cancer has the lowest survival rate.
In 2011, our organization declared a bold and aggressive vision: After seeing too little progress in pancreatic cancer survival in over half a century, the Pancreatic Cancer Action Network put a stake in the ground to double pancreatic cancer survival by 2020.
This is our Vision of Progress.
$200 MILLION on the ROAD TO 2020
An infusion of funds will allow us to significantly increase our investment in research, fueling our efforts to develop early detection tools and better treatments options for patients.
It will also support year-round government advocacy efforts on Capitol Hill and ensure federal funding for pancreatic cancer research is a national priority.
Increased funding for patient services will help improve the lives of people battling pancreatic cancer today, as well as those who are diagnosed in the future. More patients will know their options, and possibly have the opportunity to enroll in clinical trials that best match their needs.
Additional funding means we can expand the reach of Know Your TumorSM, our personalized medicine service, which provides eligible pancreatic cancer patients and their oncologists with information about the biology of their tumor. Further, information that is gathered through this service can help shape future clinical trials that drive progress for patients.
As a result of all of this activity, even greater attention will be focused on the disease across the country and around the world, and more people will have the opportunity to Wage Hope and help rewrite the future of pancreatic cancer.
OUR AGGRESSIVE STRATEGY ADDRESSES 5 key needs
We have identified five key challenges on the road to 2020, but we have a carefully considered plan of attack. Raising $200 million by 2020 will help ensure that we meet these challenges head on.
OUR LEADERSHIP IS ACCELERATING PROGRESS:
- ~100% increase in median overall survival from Phase III clinical trials since 1999
- ~600% increase in National Cancer Institute funding since 1999
- ~600% increase in the number of NCI-funded investigators studying pancreatic cancer
- ~400% increase in the number of annual peer-reviewed pancreatic cancer publications
- ~600% increase in Patient Central contacts since the program started
- ~300% increase in PurpleStride participants since 2009
YOU DRIVE PROGRESS TOWARD OUR GOAL!
We can’t achieve our goals without you! Wage Hope today in the fight against pancreatic cancer.
A very special thank you to those who have so generously supported our $200 million goal.